Key result
JenaValve Trilogy TAVR is linked to significant LV reverse remodeling in pure aortic regurgitation.
Why the study?
Does JenaValve TAVR improve LV remodeling over time in high surgical risk patients with pure, native aortic regurgitation?
Does JenaValve TAVR improve LV remodeling over time in high surgical risk patients with pure, native aortic regurgitation?
Clinical trial analysis observes left ventricular remodeling patterns in high-risk patients with native aortic regurgitation undergoing transcatheter replacement, indicating cardiac recovery.
The JenaValve Trilogy transcatheter heart valve is the first FDA approved device for treatment of high surgical risk patients with pure, native aortic regurgitation (AR). The purpose of this study was to evaluate LV remodeling over time in patients that received JenaValve TAVR in the ALIGN-AR trial and continued access registry.
No takes yet. Share an insight, caveat, or question.
Ranard et al. (2026) studied this question. Transcatheter aortic valve replacement using the JenaValve Trilogy device is associated with left ventricular reverse remodeling in high-risk patients with pure, native aortic regurgitation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: